

# Claims / Billing Education

**Sammie Asher**

Network Relations Manager  
ashers@aetna.com

2021

Volume VI

- Immunizations
- Flu
- Covid-19

Aetna-681



Aetna Better Health® of Kentucky

# Agenda

**As part of your Aetna Better Health of Kentucky's monthly claims and billing education, we will discuss:**

- Immunization Codes
- Flu
- COVID-19

## **Network Manager Spotlight – Becky Bowman – Region 5**

Anderson, Bourbon, Boyle, Clark, Estill, Fayette, Franklin, Garrard, Harrison, Jackson, Jessamine, Lincoln, Madison, Mercer, Montgomery, Nicholas, Owen, Powell, Rockcastle, Scott, Woodford

All other states excluding: IN, OH, TN, VA, & WV

---

# Immunization Codes

---



# Vaccines for Children (VFC) Program

Through the VFC program, federally provided vaccine serums are available at no charge to public and private providers for eligible children ages newborn through 18 years.

Children that meet at least one (1) of the following criteria are eligible for vaccines through the VFC program:

- Kentucky Medicaid enrolled: the child is enrolled in the Kentucky Medicaid program
- Uninsured: a child has no health insurance coverage
- Native American/Alaska Native: those children as defined in the Indian Health Care Improvement Act
- Underinsured: the child has some type of health insurance, but plan benefits do not include vaccinations

Kentucky Medicaid requires providers who administer VFC immunizations to qualified Kentucky Medicaid eligible children to enroll in the VFC program.

The Cabinet for Health and Family Services (CHFS) administers the VFC program. To enroll, providers may contact their CHFS immunization program field staff representative for their area. If you are interested in enrolling, a contact list of field staff representatives may be found at [www.chfs.ky.gov/dph/epi/Health+Care+Professionals.htm](http://www.chfs.ky.gov/dph/epi/Health+Care+Professionals.htm).

Per the Center for Disease Control (CDC):

To ensure that the correct supply of vaccine is used, participating VFC providers must verify member eligibility and status codes to distinguish whether the child is Medicaid (P1, P2, P3, P5, or P6) or KCHIP (P7) at every visit or encounter prior to rendering services.

Eligibility and status code are confirmed by accessing KYHealthNet at <https://public.kymmis.com>.



Per current billing instructions and as of dates of service January 1, 2014, vaccines will be paid by the following:

- For patients under age 19, bill Medicaid using the administration CPT and the vaccine CPT.

If the vaccine was acquired from the Vaccines for Children (VFC) program, bill modifier SL with the vaccine CPT code. If not, bill the vaccine CPT without modifier SL.

- For patients 19 and older, bill KY Medicaid using the administration CPT and the vaccine CPT. Do not use modifier SL.



# Immunization codes

CPT® Code	Description	# of Vaccine Components	Fee Schedule
90702	Diphtheria and tetanus toxoids (DT), adsorbed when administered to younger than seven years, for IM use (VIS)	2	VFC
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to <7 years, for IM use	3	VFC
90696	Diphtheria, tetanus toxoids, and acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4-6 years of age, for IM use	4	VFC
90697	Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for IM use	6	Pays Default %
90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for IM use	5	VFC
90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenza Type B, and inactivated poliovirus vaccine (DTaP-IPV/Hib), for IM use	5	VFC
90633	Hepatitis A vaccine (Hep A), pediatric/adolescent dosage, 2 dose, for IM use	1	VFC
90740	Hepatitis B vaccine (Hep B), dialysis or immunosuppressed patient dosage, 3 dose, for IM use	1	VFC
90743	Hepatitis B vaccine (Hep B), adolescent, 2 dose, for IM use	1	VFC
90744	Hepatitis B vaccine (Hep B), pediatric/adolescent dosage, 3 dose, for IM use	1	VFC
90746	Hepatitis B vaccine (Hep B), adult dosage, for IM use	1	VFC
90747	Hepatitis B vaccine (Hep B), dialysis or immunosuppressed patient dosage, 4 dose, for IM use	1	VFC
90647	Hemophilus influenza B vaccine (Hib), PRP-OMP conjugate, 3 dose, for IM use	1	VFC
90648	Hemophilus influenza B vaccine (Hib), PRP-T conjugate, 4 dose, for IM use	1	VFC
90651	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (HPV), 2 or 3 dose schedule, for IM use	1	Pays Default %
90707	Measles, mumps, and rubella virus vaccine (MMR), live, for SQ use	3	VFC
90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for SQ use	4	VFC
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for IM use	1	VFC
90621	Meningococcal recombinant lipoprotein vaccine, serogroup B, 2 or 3 dose schedule, for IM use	1	VFC
90619	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for IM use	1	Pays Default %
90734	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier, (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for IM use	1	VFC
90670	Pneumococcal conjugate vaccine, 13 valent (PCV13), for IM use	1	VFC
90732	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to 2 years or older, for subcutaneous or IM use	1	VFC
90713	Poliovirus vaccine (IPV), inactivated, for SQ or IM use	1	VFC
90680	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	1	VFC
90681	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	1	VFC
90714	Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to seven years or older, for IM use	2	VFC
90715	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to 7 years or older, for IM use	3	VFC
90716	Varicella virus vaccine (VAR), live, for subcutaneous use	1	

2020 2021 INFLUENZA VACCINES				
90672	Influenza virus vaccine, quad (LAIV), live, intranasal use		1	VFC
90674	Influenza virus vaccine, quad (ccIIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, IM		1	Phys Fee Schedule
90682	Influenza virus vaccine, quad (RIV4), derived from recombinant DNA, HA protein only, preservative and antibiotic free, IM use		1	Phys Fee Schedule
90685	Influenza virus vaccine, quad (IIIV4), split virus, preservative free, 0.25ml dose, for IM use		1	VFC
90686	Influenza virus vaccine, quad (IIIV4), split virus, preservative free, 0.5ml dosage, for IM use		1	VFC
90687	Influenza virus vaccine, quad (IIIV4), split virus, 0.25ml dosage, for IM use		1	VFC
90688	Influenza virus vaccine, quad (IIIV4), split virus, 0.5ml dosage, for IM use		1	VFC
90756	Influenza virus vaccine, quad(ccIIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for IM use		1	Phys Fee Schedule
Immunization Administration (IA) Codes				
IA Through Age 18 With Counseling* (Do not report for COVID vaccines)				
90460	IA through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid component administered (Do not report with 90471 or 90473)			VFC
+90461	IA through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered			VFC
Immunization Administration (Do not report for COVID vaccines)				
90471	IA, one injected vaccine (Do not report with 90460 or 90473)			VFC
+90472	IA, each additional injected vaccine			VFC
90473	IA by intranasal/oral route; one vaccine (Do not report with 90460 or 90471)			VFC
+90474	IA by intranasal/oral route; each additional vaccine			VFC





—  
**Flu**  
—



# Flu

The COVID -19 pandemic has highlighted the importance of reducing the spread of respiratory illnesses, like the flu. Even in a relatively mild season, the flu results in numerous hospitalizations, emergency and office visits, and missed school and work.

Over the past 35 years, annual flu-related deaths have reached as high as 50,000 in a single season.

Healthy kids and adults may be far less likely to suffer the more catastrophic consequences of the flu. However, it poses a risk to the very young, old and chronically ill in our households, schools and workplaces.

As health care professionals, you play a pivotal role in lessening the burden of flu-related suffering. According to guidance from the CDC, here are the current recommendations for flu vaccinations:

Vaccine Type	Vaccine Description	Recommended for*
Quadrivalent (4-component) Inactivated Influenza Vaccine (IIV4)	Injectable inactivated vaccine containing the influenza A(H1N1), (H3N2) and two influenza B lineage viruses predicted to be most common	People 6 months and older
Live Attenuated Influenza Vaccine (LAIV)	Intranasal live attenuated vaccine containing the influenza A(H1N1), (H3N2) and two influenza B lineage viruses predicted to be most common	Healthy non-pregnant people 2 through 49 years of age
Quadrivalent Cell Culture-Based Inactivated Influenza Vaccine (ccIIV4)	Injectable inactivated influenza vaccine manufactured using cell culture rather than eggs, containing the influenza A(H1N1), (H3N2) and two influenza B lineage viruses predicted to be most common	People 4 years and older
Quadrivalent Recombinant influenza Vaccine (RIV4)	Injectable influenza vaccine produced without the use of influenza viruses or eggs; Contains the influenza A(H1N1), (H3N2) and two influenza B lineage viruses predicted to be most common	Adults 18 years and older
Trivalent and Quadrivalent Adjuvanted Inactivated Influenza Vaccine (aIIV3 and aIIV4)	Injectable inactivated influenza vaccine containing MF59 adjuvant, designed to help promote a stronger immune response in older adults; Contains the influenza A(H1N1), (H3N2) and one or two influenza B viruses predicted to be most common	Adults 65 years and older
Quadrivalent High-Dose Inactivated Influenza Vaccine (HD-IIV4)	Injectable inactivated influenza vaccine containing four times the antigen of a standard-dose influenza vaccine, designed to help promote a stronger immune response in older adults; Contains the influenza A(H1N1), (H3N2) and two influenza B viruses predicted to be most common	Adults 65 years and older

Source: <https://www.cdc.gov/flu/pdf/freeresources/healthcare/flu-vaccine-rec-2020.pdf>

\* Licensed ages vary for different brands; consult package insert for appropriate ages for specific vaccines

[www.cdc.gov/flu/professionals/acip](http://www.cdc.gov/flu/professionals/acip)

—  
**COVID-19**  
—

# Covid-19

COVID-19 is a new disease, caused by a novel (or new) coronavirus that has not previously been seen in humans.

Because it is a new virus, scientists are learning more each day. Although most people who have COVID-19 have mild symptoms, COVID-19 can also cause severe illness and even death.

Some groups, including older adults and people who have [certain underlying medical conditions](#), are at increased risk of severe illness.

<https://www.cdc.gov/coronavirus/2019-ncov/faq.html>



# COVID-19 Vaccine

Quick Reference Guide for  
Healthcare Professionals



The table below provides basic information on the proper storage, preparation, and administration of the currently authorized COVID-19 vaccine products in the United States. For additional information and detailed clinical guidance go to the manufacturer's and CDC's webpages listed.

		Pfizer	Moderna	Janssen
GENERAL	EUA	<a href="http://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine">www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine</a>	<a href="http://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine">www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine</a>	<a href="http://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine">www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine</a>
	CDC Vaccine Information	<a href="http://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html">www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html</a>	<a href="http://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html">www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html</a>	<a href="http://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html">www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html</a>
	Manufacturer Contact information	Website: <a href="http://www.cvdvaccine.com">www.cvdvaccine.com</a> Medical information: 800-438-1985 Customer service: 800-879-3477	Website: <a href="http://www.modernatx.com">www.modernatx.com</a> Medical Information: 866-663-3762	Website: <a href="http://www.vaxcheck.jnj">www.vaxcheck.jnj</a> Medical information: 1-800-565-4008
STORAGE & HANDLING	How supplied	<b>Multidose vial:</b> 6 doses	<b>Multidose vial:</b> Maximum of 11 doses	<b>Multidose vial:</b> 5 doses
	Diluent	0.9% sodium chloride (preservative-free, normal saline) provided in the ancillary kit. Do NOT use other diluent.	None	None
	Storage Temperatures: Before Puncture	<b>Between:</b> -80°C and -60°C (-112°F and -76°F) until the expiration date -25°C and -15°C (-13°F and 5°F) for up to 2 weeks 2°C and 8°C (36°F and 46°F) for up to 120 hours (5 days)	<b>Between:</b> -50°C and -15°C (-58°F and 5°F) until the expiration date 2°C and 8°C (36°F and 46°F) for up to 30 days 8°C and 25°C (46° and 77°F) for a total of 24 hours	<b>Between:</b> 2°C and 8°C (36°F and 46°F) until the expiration date.
	Storage Temperatures: After puncture	<b>Between:</b> 2°C to 25°C (36°F to 77°F) for up to 6 hours. Discard any unused vaccine after 6 hours.	<b>Between:</b> 2°C and 25°C (36°F and 77°F) for up to 12 hours. Discard any unused vaccine after 12 hours.	<b>Between:</b> 2°C and 8°C (36°F and 46°F) for up to 6 hours. 9°C and 25°C (47°F and 77°F) for up to 2 hours. Discard any unused vaccine after these time frames.
	Transport Temperatures: Before Puncture	<b>Between:</b> -80°C and -60°C (-112°F and -76°F) -25°C and -15°C (-13°F and 5°F) 2°C and 8°C (36°F and 46°F)	<b>Between:</b> -50°C and -15°C (-58°F and 5°F) 2°C and 8°C (36°F and 46°F) for up to 12 cumulative hours.	<b>Between:</b> 2°C and 8°C (36°F and 46°F)
	Transport Temperatures: After Puncture	<b>Between:</b> 2°C to 25°C (36°F to 77°F) for up to 6 hours.	<b>Between:</b> 2°C and 25°C (36°F and 77°F) for up to 12 hours.	<b>Between:</b> 2°C and 8°C (36°F and 46°F) for up to 6 hours
Type of Vaccine	mRNA	mRNA	Viral vector	
Age Indications	16 years of age and older	18 years of age and older	18 years of age and older	
Schedule	2-doses, separated by 21 days. Both doses must be Pfizer-BioNTech vaccine	2 doses, separated by 28 days. Both doses should be Moderna vaccine	1 dose only	
Dosage	0.3 mL	0.5 mL	0.5 mL	
Needle gauge/length	22–25 gauge, 1 – 1½"	22–25 gauge, 1 – 1½"	22–25 gauge, 1 – 1½"	

\*CDC recommends transporting vaccine at refrigerated or frozen temperatures.

# COVID-19 Vaccine

Quick Reference Guide for  
Healthcare Professionals



	Pfizer	Moderna	Janssen
<b>Route</b>	Intramuscular (IM) injection	Intramuscular (IM) injection	Intramuscular (IM) injection
<b>Site</b>	Deltoid	Deltoid	Deltoid
<b>Thawing Frozen Vaccine</b>	<p><b>Between:</b> 2°C and 8°C (36°F and 46°F) or Room temperature up to 25°C (77°F) <b>Do NOT</b> refreeze thawed vaccine.</p>	<p><b>Between:</b> 2°C and 8°C (36°F and 46°F) or 8°C to 25°C (46°F to 77°F) <b>Do NOT</b> refreeze thawed vaccine.</p>	N/A
<b>Mixing Vaccine</b>	Mix vaccine with 1.8 mL of 0.9% sodium chloride (preservative-free, normal saline)	<b>Do NOT</b> mix with any diluent	<b>Do NOT</b> mix with any diluent
<b>Contraindications/Precautions</b>	<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine</li> <li>Immediate allergic reaction† of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine</li> </ul> <p><b>Note:</b> Persons who have a contraindication to an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 vaccine (see footnote).<sup>‡</sup></p> <p>Persons who have a contraindication to Janssen COVID-19 vaccine may be able to receive an mRNA COVID-19 vaccine (see footnote).<sup>‡</sup></p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>History of an immediate allergic reaction† to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies)                             <ul style="list-style-type: none"> <li>» This includes people with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is a vaccine component, but for whom it is unknown which component elicited the immediate allergic reaction.</li> </ul> </li> <li>People with a contraindication to mRNA COVID-19 vaccines have a precaution to Janssen COVID-19 Vaccine, and vice versa. (see footnote).<sup>‡</sup></li> <li>Moderate to severe acute illness</li> </ul> <p>See Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States <a href="https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html">www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html</a></p>		
<b>Post-Vaccination Observation</b>	<p><b>30 minutes:</b> Persons with a history of an immediate allergic reaction of any severity to any other vaccine or injectable therapy or a history of anaphylaxis (from any cause)</p> <p><b>15 minutes:</b> All other persons</p>		
<b>Most common adverse events</b>	<p><b>Injection site:</b> pain, swelling, redness</p> <p><b>Systemic:</b> fatigue, headache, muscle pain, chills, fever, joint pain</p>	<p><b>Injection site:</b> pain, swelling, redness</p> <p><b>Systemic:</b> fatigue, headache, muscle pain, chills, fever, nausea, joint pain</p>	<p><b>Injection site:</b> pain, redness, swelling</p> <p><b>Systemic:</b> fatigue, headache, muscle pain, nausea, fever</p>

†For the purpose of this guidance, an immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms, such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

‡Consider consultation with an allergist-immunologist to help determine if the patient can safely receive vaccination. Healthcare providers and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVID vax Project <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html>. Vaccination of these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions.

- People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to Janssen COVID-19 vaccination. People who have previously received an mRNA COVID-19 vaccine dose but have a contraindication to a second dose should wait at least 28 days to receive Janssen COVID-19 vaccine.
- People with a contraindication to Janssen COVID-19 vaccine (including due to a known polysorbate allergy) have a precaution to mRNA COVID-19 vaccination.

# COVID-19 Vaccine Codes and Crosswalk

As a reminder, members do not have any cost sharing requirements for COVID-19 vaccines, treatments, and tests. Additional information regarding COVID-19 vaccine coverage and reimbursement under the fee-for-service pharmacy benefit will be sent by Kentucky DMS's pharmacy benefit manager.

Administration Code	Description	Reimbursement Rate
0001A (1 <sup>st</sup> dose)	ADM SARSCOV2 30MCG/0.3ML 1ST	\$40.00
0002A (2 <sup>nd</sup> dose)	ADM SARSCOV2 30MCG/0.3ML 2ND	\$40.00
0011A (1 <sup>st</sup> dose)	ADM SARSCOV2 100MCG/0.5ML1ST	\$40.00
0012A (2 <sup>nd</sup> dose)	ADM SARSCOV2 100MCG/0.5ML2ND	\$40.00
0021A (1 <sup>st</sup> dose)	ADM SARSCOV2 5X1010VP/.5ML 1ST	\$40.00
0022A (2 <sup>nd</sup> dose)	ADM SARSCOV2 5X1010VP/.5ML 2ND	\$40.00
0031A	ADM SARSCOV2 VAC AD26 .5ML	\$40.00

Answers to COVID-19 questions for healthcare workers  
800-CDC-INFO (800-232-4636)

If you are a healthcare provider or health department with a question about the clinical management of COVID-19, please contact [CDC-INFO](https://www.cdc.gov/covid-19/info).



---

**Questions? We've got your back.  
Just call our Network Relations  
Department at 1-855-454-0061 or  
contact your Network Manager  
directly at any time.**

---











## Aetna Better Health® of Kentucky




### Network Relations Contact Information & Coverage Areas

Aetna Better Health of Kentucky takes great pride in our network of physicians and related professionals who serve our members with the highest level of quality care and service. We are committed to making sure our providers receive the best and latest information, technology, and tools available to ensure their success and their ability to provide for our members. We focus on operational excellence, constantly striving to eliminate redundancy and streamline processes for the benefit and value of all our partners.

Our Network Relations Team is assigned to designated areas throughout the state and are located within the communities in which they serve. This team is dedicated to meeting the needs of you, our providers. We are subject matter experts and are available to providers for education, training, and support. We assign every participating provider a Network Manager.

Aetna Better Health of Kentucky offers a provider services line which can be reached by calling 1-855-300-5528 - Monday through Friday 7 AM-7 PM.	
Credentialing applications, forms, and updates along with any demographic updates and terminations should be sent directly to: <a href="mailto:KyProviderUpdates@aetna.com">KyProviderUpdates@aetna.com</a>	
General forms, ERA enrollments, or general questions can be sent to <a href="mailto:KYProviderRelations@aetna.com">KYProviderRelations@aetna.com</a>	
Supporting Kentucky Youth, SKY Liaison Statewide	 <p>Michelle Marrs Network Relations Manager, SKY Liaison 859-221-4737 <a href="mailto:MarrsM@Aetna.com">MarrsM@Aetna.com</a></p>
 <p>Supporting Kentucky Youth - Statewide Region 3 Behavioral Health Providers All Regions - Community Mental Health Centers</p>	<p>Dustin Johnson SKY Network Manager 502-648-6526 <a href="mailto:Johnsod38@Aetna.com">Johnsod38@Aetna.com</a></p>

<p>Behavioral Health Providers</p> <p>Region 5 Region 6 Region 7 Region 8</p>		<p>Holly Smith Network Relations Manager 815-641-7411 <a href="mailto:Smith3@Aetna.com">Smith3@Aetna.com</a></p>
 <p>Association of Primary Care Physicians Community of Health Partners Cooperative Care Network Epharim McDowell Kentucky Primary Care Association The Physicians Network</p>		<p>Becky Marcum Network Relations Manager (606) 350-0579 <a href="mailto:marcumr@aetna.com">marcumr@aetna.com</a></p>
<p>Baptist Health System King's Daughters Medical System LifePoint Health System Norton Healthcare System St. Claire Medical Center University of Kentucky System University of Louisville System</p>		<p>Trista Gibson Network Manager 606-305-2705 <a href="mailto:GibsonT1@Aetna.com">GibsonT1@Aetna.com</a></p>
<p>Region 1 Ballard, Caldwell, Calloway, Carlisle, Crittenden, Fulton, Graves, Hickman, Livingston, Lyon, McCracken</p> <p>Region 2 Christian, Daviess, Hancock, Henderson, Hopkins, McLean, Muhlenberg, Ohio, Todd, Trigg, Union, Webster</p> <p>Providers in the state of Indiana</p>		<p>Gina Gullo Network Relations Manager 502-612-9958 <a href="mailto:Rgullo@Aetna.com">Rgullo@Aetna.com</a></p>
 <p>Region 3 Breckinridge, Bullitt, Carroll, Grayson, Hardin, Henry, Jefferson, Larue, Marion, Meade, Nelson, Oldham, Shelby, Spencer, Trimble, Washington</p>		<p>Connie Edelen Network Relations Manager 502-240-2122 <a href="mailto:Czedelen@Aetna.com">Czedelen@Aetna.com</a></p>
<p>Region 4 Adair, Allen, Barren, Butler, Casey, Clinton, Cumberland, Edmonson, Green, Hart, Logan, McCreary, Metcalfe, Monroe, Pulaski, Russell, Simpson, Taylor, Warren, Wayne</p> <p>Providers in the state of Tennessee</p>		<p>Sammie Asher Network Relations Manager 606-401-1573 <a href="mailto:Ashers@Aetna.com">Ashers@Aetna.com</a></p>

	<p>Region 5 Anderson, Bourbon, Boyle, Clark, Estill, Fayette, Franklin, Garrard, Harrison, Jackson, Jessamine, Lincoln, Madison, Mercer, Montgomery, Nicholas, Owen, Powell, Rockcastle, Scott, Woodford</p> <p>All other states excluding: IN, OH, TN, VA, &amp; WV</p>	<p>Becky Bowman Network Relations Manager 502-214-0399 <a href="mailto:BowmanB@Aetna.com">BowmanB@Aetna.com</a></p>
<p>Region 6 Boone, Campbell, Gallatin, Grant, Kenton, Pendleton CHI Saint Joseph Medical Group (Kentucky One)</p> <p>Providers in the state of Ohio and West Virginia</p>		<p>Jacquelyne Pack Network Manager 606-331-1075 <a href="mailto:Jmpack@Aetna.com">Jmpack@Aetna.com</a></p>
	<p>Region 7 Bath, Boyd, Bracken, Carter, Elliot, Fleming, Greenup, Lawrence, Lewis, Mason, Menifee, Morgan, Robertson, Rowan</p> <p>Region 8 Bell, Breathitt, Clay, Floyd, Harlan, Johnson, Knott, Knox, Laurel, Lee, Leslie, Letcher, Magoffin, Martin, Morgan, Owsley, Perry, Pike, Whitley, Wolfe</p> <p>Providers in the state of Virginia</p>	<p>Krystal Risner Network Manager 606-687-0310 <a href="mailto:Risnerk@Aetna.com">Risnerk@Aetna.com</a></p>

Save time by accessing our online resources.  
Be sure to check out our convenient web tools, available 24/7.

#### Health Plan Website

The health plan website is a resource for members and providers. Providers will find information such as the member handbook, provider manual and the formulary on the health plan website. Visit the Website at: [AetnaBetterHealth.com/Kentucky](https://AetnaBetterHealth.com/Kentucky)

#### Availity

Aetna Better Health of Kentucky is excited to have transitioned from our Provider Portal to Availity. This transition allows for an increase in digital interactions available to support you as you provide services for our members.

#### Functionality examples include:


Eligibility and member benefits look up  
EFT registration  
Claim status look up

Online claim submission  
PA submission and look up  
Grievance and appeals submission

Visit Availity at: <https://apps.availity.com/availity/web/public.elegant.login>



# Network Manager Spotlight




## Region 5

Anderson, Bourbon, Boyle, Clark, Estill, Fayette, Franklin, Garrard, Harrison, Jackson, Jessamine, Lincoln, Madison, Mercer, Montgomery, Nicholas, Owen, Powell, Rockcastle, Scott, Woodford

All other states excluding: IN, OH, TN, VA, & WV

Becky Bowman  
Network Relations Manager  
502-214-0399  
[BowmanB@Aetna.com](mailto:BowmanB@Aetna.com)



# Thank you



